Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2010 Jul 1;16(13):3319-21. doi: 10.1158/1078-0432.CCR-10-1059. Epub 2010 Jun 22.

ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?

Author information

1
Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA.

Abstract

Chemotherapy-induced activation of ADAM-17 results in increased growth factor shedding and activation of growth factor receptor-mediated pro-survival response. Enhanced ADAM-17 activity and HER ligand shedding results in resistance to chemotherapy in CRC. Therapies that decrease ADAM-17 activity in conjunction with current treatments may enhance response rates in advanced CRC patients.

PMID:
20570925
DOI:
10.1158/1078-0432.CCR-10-1059
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center